Local intra-articular injection of rapamycin delays articular cartilage degeneration in a murine model of osteoarthritis

Arthritis Research and Therapy

Volumn 16, Issue 1, 2014, Pages

  Takayama, Koji ^a,b   Kawakami, Yohei ^a,b   Kobayashi, Makoto ^a,b   Greco, Nick ^a,b   Cummins, James H ^b   Matsushita, Takehiko ^c   Kuroda, Ryosuke ^c   Kurosaka, Masahiro ^c   Fu, Freddie H ^a,b   Huard, Johnny ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 10; COLLAGEN TYPE 10 ALPHA 1; COLLAGENASE 3; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; UNCLASSIFIED DRUG; VASCULOTROPIN; IMMUNOSUPPRESSIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE CELL; CARTILAGE DEGENERATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; OSTEOARTHRITIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; TREATMENT OUTCOME; ANIMAL; DISEASE MODEL; DRUG EFFECTS; INTRAARTICULAR DRUG ADMINISTRATION; METABOLISM; PATHOLOGY;

ANIMALS; CARTILAGE, ARTICULAR; DISEASE MODELS, ANIMAL; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRA-ARTICULAR; MALE; MICE; OSTEOARTHRITIS; SIROLIMUS;

EID: 84924287483     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-014-0482-4     Document Type: Article

References (39)

1. Vignon E, Arlot M, Meunier P, Vignon G: Quantitative histological changes in osteoarthritic hip cartilage. Morphometric analysis of 29 osteoarthritic and 26 normal human femoral heads. Clin Orthop Relat Res 1974, 103:269-278.
2. Kronenberg HM: Developmental regulation of the growth plate. Nature 2003, 423:332-336.
3. Levine B, Klionsky DJ: Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 2004, 6:463-477.
4. Levine B, Kroemer G: Autophagy in the pathogenesis of disease. Cell 2008, 132:27-42.
5. Eskelinen EL, Saftig P: Autophagy: a lysosomal degradation pathway with a central role in health and disease. Biochim Biophys Acta 2009, 1793:664-673.
6. Mizushima N, Levine B, Cuervo AM, Klionsky DJ: Autophagy fights disease through cellular self-digestion. Nature 2008, 451:1069-1075.
7. Komatsu M, Ueno T, Waguri S, Uchiyama Y, Kominami E, Tanaka K: Constitutive autophagy: vital role in clearance of unfavorable proteins in neurons. Cell Death Differ 2007, 14:887-894.
8. Sasaki H, Takayama K, Matsushita T, Ishida K, Kubo S, Matsumoto T, Fujita N, Oka S, Kurosaka M, Kuroda R: Autophagy modulates osteoarthritis-related gene expression in human chondrocytes. Arthritis Rheum 2012, 64:1920-1928.
9. Carames B, Hasegawa A, Taniguchi N, Miyaki S, Blanco FJ, Lotz M: Autophagy activation by rapamycin reduces severity of experimental osteoarthritis. Ann Rheum Dis 2012, 71:575-581.
10. Koehl GE, Andrassy J, Guba M, Richter S, Kroemer A, Scherer MN, Steinbauer M, Graeb C, Schlitt HJ, Jauch KW, Geissler EK: Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004, 77:1319-1326.
11. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global ARCC, Global ARCC Trial: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
12. Cravedi P, Ruggenenti P, Remuzzi G: Sirolimus to replace calcineurin inhibitors? Too early yet. Lancet 2009, 373:1235-1236.
13. Glasson SS, Blanchet TJ, Morris EA: The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. Osteoarthritis Cartilage 2007, 15:1061-1069.
14. Carames B, Taniguchi N, Seino D, Blanco FJ, D'Lima D, Lotz M: Mechanical injury suppresses autophagy regulators and pharmacologic activation of autophagy results in chondroprotection. Arthritis Rheum 2012, 64:1182-1192.
15. Glasson SS, Chambers MG, Van Den Berg WB, Little CB: The OARSI histopathology initiative - recommendations for histological assessments of osteoarthritis in the mouse. Osteoarthritis Cartilage 2010, 18:S17-S23.
16. Wei T, Kulkarni NH, Zeng QQ, Helvering LM, Lin X, Lawrence F, Hale L, Chambers MG, Lin C, Harvey A, Ma YL, Cain RL, Oskins J, Carozza MA, Edmondson DD, Hu T, Miles RR, Ryan TP, Onyia JE, Mitchell PG: Analysis of early changes in the articular cartilage transcriptisome in the rat meniscal tear model of osteoarthritis: pathway comparisons with the rat anterior cruciate transection model and with human osteoarthritic cartilage. Osteoarthritis Cartilage 2010, 18:992-1000.
17. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ: Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007, 26:1932-1940.
18. Shi X, Shen B, Yang J, Kang P, Zhou Z, Pei F: In vivo kinematics comparison of fixed- and mobile-bearing total knee arthroplasty during deep knee bending motion. Knee Surg Sports Traumatol Arthrosc 2014, 22:1612-1618.
19. Yin W, Park JI, Loeser RF: Oxidative stress inhibits insulin-like growth factor-I induction of chondrocyte proteoglycan synthesis through differential regulation of phosphatidylinositol 3-Kinase-Akt and MEK-ERK MAPK signaling pathways. J Biol Chem 2009, 284:31972-31981.
20. Cravero JD, Carlson CS, Im HJ, Yammani RR, Long D, Loeser RF: Increased expression of the Akt/PKB inhibitor TRB3 in osteoarthritic chondrocytes inhibits insulin-like growth factor 1-mediated cell survival and proteoglycan synthesis. Arthritis Rheum 2009, 60:492-500.
21. Starkman BG, Cravero JD, Delcarlo M, Loeser RF: IGF-I stimulation of proteoglycan synthesis by chondrocytes requires activation of the PI 3-kinase pathway but not ERK MAPK. The Biochemical journal 2005, 389:723-729.
22. Pesesse L, Sanchez C, Henrotin Y: Osteochondral plate angiogenesis: a new treatment target in osteoarthritis. Joint Bone Spine 2011, 78:144-149.
23. Lotz M: Osteoarthritis year 2011 in review: biology. Osteoarthritis Cartilage 2012, 20:192-196.
24. Matsumoto T, Cooper GM, Gharaibeh B, Meszaros LB, Li G, Usas A, Fu FH, Huard J: Cartilage repair in a rat model of osteoarthritis through intraarticular transplantation of muscle-derived stem cells expressing bone morphogenetic protein 4 and soluble Flt-1. Arthritis Rheum 2009, 60:1390-1405.
25. Bjornsti MA, Houghton PJ: The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004, 4:335-348.
26. Hsu T, Adereth Y, Kose N, Dammai V: Endocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility. J Biol Chem 2006, 281:12069-12080.
27. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002, 8:128-135.
28. van der Kraan PM, van den Berg WB: Chondrocyte hypertrophy and osteoarthritis: role in initiation and progression of cartilage degeneration? Osteoarthritis Cartilage 2012, 20:223-232.
29. Fuerst M, Bertrand J, Lammers L, Dreier R, Echtermeyer F, Nitschke Y, Rutsch F, Schafer FK, Niggemeyer O, Steinhagen J, Lohmann CH, Pap T, Rüther W: Calcification of articular cartilage in human osteoarthritis. Arthritis Rheum 2009, 60:2694-2703.
30. Fuerst M, Niggemeyer O, Lammers L, Schafer F, Lohmann C, Ruther W: Articular cartilage mineralization in osteoarthritis of the hip. BMC Musculoskelet Disord 2009, 10:166.
31. Pesesse L, Sanchez C, Delcour JP, Bellahcene A, Baudouin C, Msika P, Henrotin Y: Consequences of chondrocyte hypertrophy on osteoarthritic cartilage: potential effect on angiogenesis. Osteoarthritis Cartilage 2013, 21:1913-1923.
32. McMullen JR, Sherwood MC, Tarnavski O, Zhang L, Dorfman AL, Shioi T, Izumo S: Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 2004, 109:3050-3055.
33. Park IH, Erbay E, Nuzzi P, Chen J: Skeletal myocyte hypertrophy requires mTOR kinase activity and S6K1. Exp Cell Res 2005, 309:211-219.
34. Sakaguchi M, Isono M, Isshiki K, Sugimoto T, Koya D, Kashiwagi A: Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Biochem Biophys Res Commun 2006, 340:296-301.
35. Alvarez-Garcia O, Carbajo-Perez E, Garcia E, Gil H, Molinos I, Rodriguez J, Ordonez FA, Santos F: Rapamycin retards growth and causes marked alterations in the growth plate of young rats. Pediatr Nephrol 2007, 22:954-961.
36. Alvarez-Garcia O, Garcia-Lopez E, Loredo V, Gil-Pena H, Rodriguez-Suarez J, Ordonez FA, Carbajo-Perez E, Santos F: Rapamycin induces growth retardation by disrupting angiogenesis in the growth plate. Kidney Int 2010, 78:561-568.
37. Kirsch T, von der Mark K: Remodelling of collagen types I, II and X and calcification of human fetal cartilage. Bone Miner 1992, 18:107-117.
38. Nurminskaya M, Linsenmayer TF: Identification and characterization of up-regulated genes during chondrocyte hypertrophy. Dev Dyn 1996, 206:260-271.
39. Alvarez J, Balbin M, Santos F, Fernandez M, Ferrando S, Lopez JM: Different bone growth rates are associated with changes in the expression pattern of types II and X collagens and collagenase 3 in proximal growth plates of the rat tibia. J Bone Miner Res 2000, 15:82-94.